CA2690865A1 - Methods of diagnosing and treating cancer - Google Patents

Methods of diagnosing and treating cancer Download PDF

Info

Publication number
CA2690865A1
CA2690865A1 CA2690865A CA2690865A CA2690865A1 CA 2690865 A1 CA2690865 A1 CA 2690865A1 CA 2690865 A CA2690865 A CA 2690865A CA 2690865 A CA2690865 A CA 2690865A CA 2690865 A1 CA2690865 A1 CA 2690865A1
Authority
CA
Canada
Prior art keywords
subject
rrm1
level
expression
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2690865A
Other languages
English (en)
French (fr)
Inventor
Gerold Bepler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida St. Petersburg
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2690865A1 publication Critical patent/CA2690865A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2690865A 2007-06-15 2008-06-13 Methods of diagnosing and treating cancer Abandoned CA2690865A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US94415707P 2007-06-15 2007-06-15
US60/944,157 2007-06-15
US3955508P 2008-03-26 2008-03-26
US61/039,555 2008-03-26
PCT/US2008/066918 WO2008157353A1 (en) 2007-06-15 2008-06-13 Methods of diagnosing and treating cancer

Publications (1)

Publication Number Publication Date
CA2690865A1 true CA2690865A1 (en) 2008-12-24

Family

ID=40156627

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2690865A Abandoned CA2690865A1 (en) 2007-06-15 2008-06-13 Methods of diagnosing and treating cancer

Country Status (12)

Country Link
US (1) US20090017012A1 (enExample)
EP (1) EP2171086B1 (enExample)
JP (1) JP5479332B2 (enExample)
KR (1) KR20100044780A (enExample)
CN (1) CN101815793A (enExample)
AU (1) AU2008266048A1 (enExample)
BR (1) BRPI0813364A2 (enExample)
CA (1) CA2690865A1 (enExample)
ES (1) ES2401475T3 (enExample)
MX (1) MX2009013646A (enExample)
RU (1) RU2010101093A (enExample)
WO (1) WO2008157353A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008541701A (ja) * 2005-05-04 2008-11-27 ユニヴァーシティ オブ サウス フロリダ がんの対象における処置応答の予測
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
EP2350320A4 (en) * 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES
JP5024736B2 (ja) 2009-10-15 2012-09-12 住友電気工業株式会社 発電システム
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
US9393318B2 (en) * 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
KR101602532B1 (ko) * 2013-08-29 2016-03-11 경북대학교 산학협력단 위암의 재발 가능성 예측을 위한 정보제공 방법
JP6681475B2 (ja) * 2015-10-26 2020-04-15 サイフェローム がん患者のゲノム塩基配列変異情報と生存情報を利用したカスタマイズ型の薬物選択方法及びシステム
EP4178448A4 (en) * 2020-07-10 2025-06-18 Progenics Pharmaceuticals, Inc. Methods of making prostate cancer treatment decisions
CN113957145B (zh) * 2021-10-19 2023-09-26 中国医学科学院肿瘤医院 m6A相关lncRNA在预测小细胞肺癌预后和化疗反应的应用
CN114564622B (zh) * 2022-03-03 2025-07-25 苏州良医汇网络科技有限公司 一种tnm分期表录入系统的方法、装置以及设备

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705336A (en) * 1995-03-07 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Assay for sensitivity of tumors to DNA-platinating chemotherapy
US20020090642A1 (en) * 1995-12-11 2002-07-11 Patrick G. Johnston Methods for determining the prognosis of breast cancer using antibodies specific for thymidylate synthase
WO1998033518A1 (en) * 1997-02-04 1998-08-06 Sloan-Kettering Institute For Cancer Research Mutants of thymidylate synthase and uses thereof
US6087489A (en) * 1998-06-02 2000-07-11 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of human thymidylate synthase expression
EP1191096B1 (en) * 1999-06-28 2011-10-12 Yusuke Nakamura Ovel protein and dna thereof
US6248535B1 (en) * 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6582919B2 (en) * 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US7049059B2 (en) * 2000-12-01 2006-05-23 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
US6518416B1 (en) * 2000-12-01 2003-02-11 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6956111B2 (en) * 2001-03-02 2005-10-18 Response Genetics, Inc. Method of determining dihydropyrimidine dehydrogenase gene expression
US6686155B2 (en) * 2001-06-14 2004-02-03 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
WO2004031408A1 (en) * 2002-09-30 2004-04-15 F.Hoffmann-La Roche Ag Oligonucleotides for genotyping thymidylate synthase gene
AU2004285103A1 (en) * 2003-09-29 2005-05-12 Pathwork Diagnostics, Inc. Systems and methods for detecting biological features
JP2008541701A (ja) * 2005-05-04 2008-11-27 ユニヴァーシティ オブ サウス フロリダ がんの対象における処置応答の予測

Also Published As

Publication number Publication date
US20090017012A1 (en) 2009-01-15
RU2010101093A (ru) 2011-07-20
JP2010530746A (ja) 2010-09-16
ES2401475T3 (es) 2013-04-19
CN101815793A (zh) 2010-08-25
WO2008157353A1 (en) 2008-12-24
MX2009013646A (es) 2010-03-30
EP2171086A1 (en) 2010-04-07
EP2171086A4 (en) 2010-10-13
EP2171086B1 (en) 2012-12-19
JP5479332B2 (ja) 2014-04-23
KR20100044780A (ko) 2010-04-30
AU2008266048A1 (en) 2008-12-24
BRPI0813364A2 (pt) 2014-12-30

Similar Documents

Publication Publication Date Title
Onoue et al. UGT1A1* 6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients
US7795033B2 (en) Methods to predict the outcome of treatment with antidepressant medication
Kang et al. Aberrant allele-switch imprinting of a novel IGF1R intragenic antisense non-coding RNA in breast cancers
DK2285980T3 (en) NATURAL KILLER p30 (NKp30) DYSFUNCTION AND THE BIOLOGICAL APPLICATIONS THEREOF
Ling et al. Hypermethylation-modulated down-regulation of CDH1 expression contributes to the progression of esophageal cancer
CN102732600A (zh) 肿瘤个性化治疗基因测评及套组方法
Jin et al. EML4-ALK fusion gene in Korean non-small cell lung cancer
Pichert et al. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
JP2024504367A (ja) がんを治療及び改善するための方法
Ueda et al. Glutathione S‐transferase GSTM1, GSTT1 and p53 codon 72 polymorphisms in human tumor cells
CN108192974A (zh) 长链非编码rna linc00842作为生物标志物在制备肺腺癌预后检测制剂中的应用
EP2370595B1 (en) Method of stratifying breast cancer patients based on gene expression
Zhang et al. Predictive potential of glutathione S-transferase polymorphisms for prognosis of osteosarcoma patients on chemotherapy
ES2377062T3 (es) Métodos para determinar un régimen quimioterapéutico basado en la pérdida de heterocigosidad en el locus de timidilato sintasa
CN102676644A (zh) 前列腺癌发病风险基因评估方法及诊断试剂盒
CA2479968A1 (en) Protein c and endothelial protein c receptor polymorphisms as indicators of patient outcome
Fernández-Contreras et al. Combination of polymorphisms within 5'and 3'untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients
Passamonti et al. Blast phase of essential thrombocythemia: A single center study
CN112746100A (zh) 用于kir基因分型的引物、试剂盒及方法
Gibadulinová et al. Expression of S100P protein correlates with and contributes to the tumorigenic capacity of HeLa cervical carcinoma cells
Arifin et al. EGFR activating aberration occurs independently of other genetic aberrations or telomerase activation in adenocarcinoma of the lung
Vannucchi et al. A phase 2 study of pemigatinib (FIGHT-203; INCB054828) in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 gene rearrangement [poster]
Wang et al. Effects of the ANXA6 polymorphisms on glioma risk and patients prognosis
CN108192975A (zh) 长链非编码rna linc00559作为生物标志物在制备肺鳞癌预后检测制剂中的应用
Javadlar et al. RUNX1 variant as a genetic predisposition factor for acute myeloid leukemia

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130515

FZDE Discontinued

Effective date: 20160126